Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors

Gene Therapy

Volumn 8, Issue 19, 2001, Pages 1456-1463

  Peng, K W ^a   Pham, L ^a   Ye, H ^a   Zufferey, R ^b   Trono, D ^b   Cosset, F L ^c   Russell, S J ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^c UNIVERSITÉ DE LYON   (France)

Author keywords

Biodistribution; Lentiviral vectors; Targeting

Indexed keywords

BLOOD CLOTTING FACTOR 10A; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; LUCIFERASE; POLYPEPTIDE; PROTEINASE; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; VIRUS VECTOR;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL MODEL; ARTICLE; BIOTECHNOLOGY; BONE MARROW; BRAIN; CELL CYCLE; CELL POPULATION; CELL TYPE; CHIMERA; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME SUBSTRATE; FEMALE; GENE EXPRESSION; GENE TARGETING; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HEART; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VIVO STUDY; INFUSION; KIDNEY; LENTIVIRINAE; LIVER; LUNG; MURINE LEUKEMIA VIRUS; NONHUMAN; OVARY; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; SKELETAL MUSCLE; SOLUBILITY; SPLEEN; SURFACE PROPERTY; TISSUE DISTRIBUTION; VIRUS INFECTIVITY; VIRUS PARTICLE;

ANIMALS; EPIDERMAL GROWTH FACTOR; FEMALE; GENE EXPRESSION; GENE TARGETING; GENETIC VECTORS; HIV-1; HUMANS; LEUKEMIA VIRUS, MURINE; LIVER; LUCIFERASES; MICE; MICE, INBRED BALB C; MYOCARDIUM; POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT PROTEINS; SPLEEN;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS; MURINAE; MURINE LEUKEMIA VIRUS; RNA VIRUSES;

EID: 0034782616     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301552     Document Type: Article

References (40)

1. Integration of murine leukemia virus DNA depends on mitosis
2. Lentiviral vectors: Excellent tools for experimental gene transfer and promising candidates for gene therapy
3. Lentiviral vectors: Turning a deadly foe into a therapeutic agent
4. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus
5. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector
6. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector
7. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors
8. Rescue from photoreceptor degeneration in the rd mouse by human immunodeficiency virus vector-mediated gene transfer
9. Efficient lentiviral transduction of liver requires cell cycling in vivo
10. Generation of targeted retroviral vectors by using single-chain variable fragment: An approach to in vivo gene delivery
11. Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMLV gp70 envelope protein
12. Pseudotyping of murine leukemia virus with the envelope glycoproteins of HIV generates a retroviral vector with specificity of infection for CD4-expressing cells
13. Targeting of HIV- and SIV-infected cells by CD4-chemokine receptor pseudotypes
14. Retrovirus vectors displaying the IgG-binding domain of protein A
15. Retroviral vector targeting to melanoma cells by single-chain antibody incorporation in envelope
16. + lymphoid cells
17. The hypervariable domain of the murine leukemia virus surface protein tolerates large insertions and deletions, enabling development of a retroviral particle display system
18. A TVA-single-chain antibody fusion protein mediates specific targeting of a subgroup A avian leukosis virus vector to cells expressing a tumor-specific form of epidermal growth factor receptor
19. Targeting human T cells by retroviral vectors displaying antibody domains selected from a phage display library
20. Targeting retrovirus to cancer cells expressing a mutant EGF receptor by insertion of a single chain antibody variable domain in the envelope glycoprotein receptor binding lobe
21. Viral vector targeting
22. Retroviral display of antibody fragments: Interdomain spacing strongly influences vector infectivity
23. Retroviral retargeting by envelopes expressing an N-terminal binding domain
24. Masking of retroviral envelope functions by oligomerising peptide adaptors
25. Inverse targeting of retroviral vectors: Selective gene transfer in a mixed population of hematopoietic and nonhematopietic cells
26. A gene delivery system activatable by disease associated matrix metalloproteinases
27. Retroviral gene delivery system activatable by plasmin
28. Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors
29. Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor
30. Systemic administration in a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice
31. In vivo cell type-specific gene delivery with retroviral vectors that display single chain antibodies
32. Concentration of viral vectors by co-precipitation with calcium phosphate
33. VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum
34. Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors
35. Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector
36. Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse
37. Biodistribution of radioactive epidermal growth factor in normal and tumor bearing mice
38. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo
39. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery
40. Targeting of retroviral vectors through protease-substrate interactions